Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)Helena A. Yu, Jonathan W. Riess, Paul D. Smith et al.|Clinical Lung Cancer|2021Cited by 73
P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib TherapyHelena A. Yu, Jonathan W. Riess, Sarah B. Goldberg et al.|Journal of Thoracic Oncology|2019Cited by 26
Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).Fabrice André, Komal Jhaveri, Erika Hamilton et al.|Journal of Clinical Oncology|2022Cited by 25
P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line OsimertinibB.C. Cho, Helena A. Yu, Zofia Piotrowska et al.|Journal of Thoracic Oncology|2021Cited by 3